ASCO® GI 2025 Insights: Real-World Outcomes of Durvalumab +/- Tremelimumab in Unresectable HCC - Preliminary Results From the International DT-Real Study | VuMedi

Find latest Hepatocellular Cancer videos · 200+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

10 seconds

Playback speed

This video is featured in the Insights from 2025 ASCO® GI Annual Meeting

Insights from 2025 ASCO® GI Annual Meeting

ASCO® GI 2025 Insights: Real-World Outcomes of Durvalumab +/- Tremelimumab in Unresectable HCC - Preliminary Results From the International DT-Real Study

By Insights from 2025 ASCO® GI Annual Meeting FEATURING Ciro Celsa

By Insights from 2025 ASCO® GI Annual Meeting FEATURING Ciro Celsa

92 views

February 4, 2025

Comments 1

Login to view comments. Click here to Login